COVINO GREGORY F
Form 4
January 22, 2019

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

OMB APPROVAL
OMB Number:
Expires: January 31,
Estimated average burden hours per response...
0.5
(Print or Type Responses)

| 1. Name and Address of Reporting Person * COVINO GREGORY F | 2. Issuer Name and Ticker or Trading Symbol |
| :---: | :---: |
|  | TESARO, Inc. [TSRO] |
| (Last) (First) (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) |
| C/O TESARO, INC., 1000 WINTER | 01/22/2019 |
| STREET |  |
| (Street) | 4. If Amendment, Date Original Filed(Month/Day/Year) |

WALTHAM,, MA 02451
(City) (State) (Zip)

| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. <br> Transact <br> Code <br> (Instr. 8) <br> Code | 4. Securi nAcquired Disposed (Instr. 3, <br> Amount | ies <br> (A) 0 <br> of (D <br> 4 and <br> (A) or <br> (D) | Price | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Common Stock | 01/22/2019 |  | U | $\begin{aligned} & 2,156 \\ & (1) \end{aligned}$ | D | \$ 75 | 0 | D |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of
information contained in this form are not
required to respond unless the form 1474
displays a currently valid OMB control
number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)


## Reporting Owners

## Reporting Owner Name / Address

## Relationships

Director $10 \%$ Owner Officer Other

## COVINO GREGORY F

C/O TESARO, INC., 1000 WINTER STREET
WALTHAM,, MA 02451
SVP, CAO, PAO

## Signatures

/s/ Joseph L. Farmer, Attorney-in-Fact
${ }_{-}^{* *}$ Signature of Reporting Person
01/22/2019

Date

## Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. $78 \mathrm{ff}(\mathrm{a})$.
Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to
(1) purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $\$ 75.00$ per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
(2) Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $\$ 75.00$ per share.

## Edgar Filing: COVINO GREGORY F - Form 4

(4) Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $\$ 75.00$ was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $\$ 75.00$ over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $\$ 75.00$ was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

